Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(11 sites) United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California USC Norris Comprehensive Cancer Center, Los Angeles, California Sarah Cannon Research Institute (SCRI), Denver, Colorado University of Iowa, Iowa City, Iowa Norton Cancer Institute, Louisville, Kentucky Show all 11 locations Key details Phase
Early testing / Safety & dosing
Sponsor
Phanes Therapeutics
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~258 participants
Primary completion
December 2027
Last updated November 2025